Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has a pharmacologically complex interaction profile rooted in three distinct metabolic pathways — one per component of the fixed-dose tablet. Understanding these mechanisms is essential for managing co-administered therapies safely: some combinations carry absolute contraindications with life-threatening consequences, while others require only timing adjustments or laboratory surveillance. This page is a clinical reference covering the pharmacokinetic mechanisms, AUC data, and prescribing frameworks for each interaction category documented in the Biktarvy prescribing information and 2026 HIV treatment guidelines. For patient-facing guidance on supplement timing and dietary interactions, see our foods and dietary interactions guide.
How Biktarvy Is Metabolized: The Three Pharmacokinetic Pathways
- Bictegravir (BIC) is metabolized primarily by CYP3A4 and UGT1A1. Inducers of these enzymes lower bictegravir plasma concentrations — in severe cases to subtherapeutic levels insufficient to suppress HIV replication.
- Tenofovir alafenamide (TAF) is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Drugs that inhibit P-gp/BCRP can raise TAF exposure; at clinically relevant concentrations TAF itself is not an inhibitor of P-gp or BCRP.
- Emtricitabine (FTC) undergoes renal elimination via organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins (MATE1, MATE2-K). FTC and BIC together inhibit these transporters, raising plasma concentrations of renally cleared co-drugs — particularly metformin and dofetilide.
The two highest-risk interaction categories: First, drugs that strongly induce CYP3A4 (principally rifampin) can reduce bictegravir AUC by up to 75%, driving plasma levels below the protein-adjusted IC90 and creating conditions for viral rebound and integrase resistance. Second, drugs eliminated by MATE1/MATE2-K (particularly dofetilide) accumulate to toxic concentrations when these transporters are inhibited — a mechanism that carries a risk of fatal arrhythmia.
Pharmacokinetic Data: Documented AUC Changes
| Co-administered Drug | Effect on Biktarvy Components | Effect on Co-Drug | AUC Change |
|---|---|---|---|
| Rifampin | Strong CYP3A/P-gp induction | — | BIC AUC ↓75% |
| Carbamazepine | CYP3A induction | — | BIC AUC ↓69% |
| Rifabutin | Moderate CYP3A/P-gp induction | — | BIC AUC ↓38% |
| Aluminum/magnesium antacid (fasted, simultaneous) | Chelation in GI lumen | — | BIC AUC ↓79% |
| Aluminum/magnesium antacid (with food, simultaneous) | Chelation, partly offset by food | — | BIC AUC ↓47% |
| Calcium carbonate (fasted, simultaneous) | Chelation in GI lumen | — | BIC AUC ↓33% |
| Ferrous fumarate / iron (fasted, simultaneous) | Chelation in GI lumen | — | BIC AUC ↓63% |
| Dofetilide | — | MATE1/MATE2-K inhibition raises dofetilide exposure | Absolute contraindication |
| Metformin | — | OCT2/MATE1 inhibition raises metformin concentration | Metformin AUC ↑39% |
| St. John’s Wort | CYP3A4/P-gp induction | — | Absolute contraindication |
| Warfarin | — | Variable pharmacokinetic interaction | Monitor INR |
Contraindicated Drugs: Mechanisms and Clinical Consequences
The following drugs cannot be co-administered with Biktarvy. If a patient on Biktarvy requires one of these agents, a full antiretroviral regimen review and planned switch must occur before the interacting drug is initiated.
| Drug | Drug Class | Pharmacokinetic Mechanism | Clinical Consequence |
|---|---|---|---|
| Rifampin (Rifadin) | Anti-tuberculosis / Antibiotic | Strong CYP3A4 and P-gp inducer — reduces bictegravir AUC ~75% | HIV treatment failure + integrase resistance |
| Rifapentine (Priftin) | Anti-tuberculosis | Strong CYP3A4 and P-gp inducer — parallel mechanism to rifampin | HIV treatment failure + integrase resistance |
| St. John’s Wort | Herbal / Botanical | CYP3A4 and P-gp inducer — bictegravir falls to subtherapeutic levels | HIV treatment failure + integrase resistance |
| Dofetilide (Tikosyn) | Class III Antiarrhythmic | FTC and BIC inhibit renal MATE1 and MATE2-K transporters, raising dofetilide to QT-prolonging levels | Life-threatening ventricular arrhythmia (TdP) |
Major Interactions: Dose Adjustments, Monitoring, and Clinical Management
| Drug / Class | Status | Effect | Recommended Action |
|---|---|---|---|
| Aluminum/magnesium antacids | Strict timing | Chelation reduces bictegravir GI absorption; fasted simultaneous BIC AUC ↓79% | Take Biktarvy ≥2 h before, or ≥6 h after, the antacid (not bidirectional) |
| Calcium or iron (supplements/antacids) | Take with food | Fasted simultaneous BIC AUC ↓33% (calcium) / ↓63% (iron); effect neutralized with food | Take together with food, or separate by ≥2 h |
| Carbamazepine | Not recommended | CYP3A inducer — bictegravir AUC ↓~69% | Switch to lamotrigine or levetiracetam |
| Oxcarbazepine | Not recommended | CYP3A inducer | Switch to safer anticonvulsant |
| Phenobarbital / Primidone | Not recommended | CYP3A inducer | Switch to safer anticonvulsant |
| Phenytoin / Fosphenytoin | Not recommended | CYP3A inducer | Switch to safer anticonvulsant |
| Rifabutin | Not recommended | Moderate CYP3A/P-gp inducer — bictegravir AUC ↓~38% | Regimen switch recommended |
| Metformin | Monitor renal function | OCT2/MATE1 inhibition raises metformin AUC ~39% (modest; not clinically significant with normal renal function) | Monitor eGFR; closer monitoring and possible metformin dose adjustment in moderate renal impairment |
| Atorvastatin / Rosuvastatin | No dose cap | No clinically significant Biktarvy-specific interaction documented in the PI | Standard dosing; routine muscle-symptom awareness per statin label |
| Simvastatin / Lovastatin | Class-level caution | General ART prudence; no Biktarvy-specific interaction documented | Prefer pravastatin or pitavastatin per HIV lipid-management practice |
| Warfarin | Monitor INR | Variable pharmacokinetic interaction | Check INR within 1–2 weeks of starting/stopping Biktarvy |
| Hormonal contraceptives | No interaction | No clinically significant interaction identified | No dose adjustment required |
| Methadone | No interaction | No clinically significant interaction identified | No dose adjustment required |
| Buprenorphine / naloxone | No interaction | No clinically significant interaction documented | No dose adjustment required |
Chelation Pharmacokinetics: How Polyvalent Cations Impair Bictegravir Absorption
Bictegravir contains a metal-chelating pharmacophore — specifically a diketo acid moiety — that coordinates with polyvalent metal ions in the gastrointestinal lumen. When bictegravir is present simultaneously with divalent or trivalent cations (Ca²+, Mg²+, Al³+, Fe²+/Fe³+), stable insoluble chelate complexes form before intestinal absorption can occur.
The magnitude of the interaction depends on which cation is involved, the timing relative to the bictegravir dose, and whether the dose is taken with food. Taken simultaneously under fasting conditions, an aluminum/magnesium hydroxide antacid reduces bictegravir AUC by approximately 79%, calcium carbonate by approximately 33%, and ferrous fumarate (iron) by approximately 63%. Both timing and food substantially mitigate these effects: bictegravir taken 2 hours before an aluminum/magnesium antacid shows only about a 13% AUC reduction, whereas taking it 2 hours after the antacid still reduces AUC by roughly 52% — so the separation is not bidirectional. Calcium and iron, by contrast, have negligible effect on bictegravir when the dose is taken with food.
Anticonvulsants: CYP3A4 Induction Risk and Preferred Alternatives
Anticonvulsants Not Recommended With Biktarvy
- Carbamazepine (Tegretol, Carbatrol) — strong CYP3A4 inducer; bictegravir AUC ↓~69%
- Oxcarbazepine (Trileptal) — moderate CYP3A4 inducer; not recommended
- Phenobarbital and primidone (Mysoline) — CYP3A4/2C9/2C19 inducer; not recommended
- Phenytoin and fosphenytoin (Dilantin, Cerebyx) — CYP3A4/2C9 inducer; not recommended
Preferred Anticonvulsant Alternatives
- Lamotrigine (Lamictal) — UGT glucuronidation, minimal CYP3A4 involvement; no clinically significant effect on bictegravir
- Levetiracetam (Keppra) — renally cleared; no CYP involvement; no Biktarvy interaction
- Gabapentin (Neurontin) — excreted renally unchanged; no CYP3A4 induction
Prescribing coordination: Any anticonvulsant change in a patient on Biktarvy requires coordination between neurology and infectious disease. Abrupt anticonvulsant withdrawal carries independent seizure risk.
Statins and Biktarvy: What the Label Actually Supports
Unlike ritonavir- or cobicistat-boosted HIV regimens, Biktarvy contains no pharmacokinetic booster, so it does not impose the statin dose caps associated with boosted therapy. The Biktarvy prescribing information does not document a clinically significant interaction with atorvastatin or rosuvastatin, and independent professional interaction checkers report no interaction between Biktarvy and these statins. General antiretroviral lipid-management prudence still applies:
- Pravastatin and pitavastatin: lowest interaction burden across HIV therapy; reasonable first choices when statin therapy is indicated.
- Atorvastatin and rosuvastatin: no Biktarvy-specific dose cap; use at standard doses guided by lipid goals and the statin’s own label, with routine muscle-symptom awareness.
- Simvastatin and lovastatin: commonly avoided in patients on antiretroviral therapy as a class-level precaution, reflecting their well-documented interactions with boosted regimens rather than a specific Biktarvy effect.
Bottom line: Statin selection on Biktarvy follows standard cardiovascular lipid guidelines and each statin’s own prescribing information, not a Biktarvy-imposed dose ceiling. There is no label-documented bictegravir/TAF pharmacokinetic interaction that requires reducing a statin dose.
Metformin and Renal Transporter Inhibition
Metformin is eliminated almost exclusively by active renal secretion via OCT2 and MATE1. Both bictegravir and emtricitabine inhibit these transporters, raising steady-state metformin exposure by approximately 39% in healthy volunteers — a modest change that studies have found not to be clinically significant in patients with normal renal function, with no meaningful effect on glucose control or lactate. Management: establish baseline eGFR before initiating; monitor renal function periodically; and apply closer monitoring, with metformin dose adjustment if needed, in patients with moderate renal impairment, where reduced clearance raises the risk of lactic acidosis.
St. John’s Wort: Absolute Contraindication
St. John’s Wort is absolutely contraindicated with Biktarvy. Reduction of bictegravir to subtherapeutic plasma concentrations creates conditions for HIV replication under partial integrase inhibition pressure. Viral variants selected under these conditions may carry integrase resistance mutations that confer cross-resistance to other integrase strand transfer inhibitors including dolutegravir and raltegravir.
Laboratory Monitoring by Co-Medication Category
| Co-Medication | Primary Monitoring Parameter | Recommended Timing |
|---|---|---|
| Metformin | eGFR; serum lactate if symptoms develop | Baseline eGFR before initiating; repeat periodically, more closely in renal impairment |
| Warfarin | INR (prothrombin time) | Within 1–2 weeks of starting or stopping Biktarvy |
| Atorvastatin / Rosuvastatin | Muscle-symptom assessment; CK if symptomatic | Per standard statin monitoring; no Biktarvy-specific schedule required |
| Rifabutin (if clinically necessary) | HIV viral load | Monthly viral load for first 3 months; quarterly thereafter |
| All patients on Biktarvy (routine) | eGFR, creatinine, urine protein/glucose; LFTs; lipid panel; HIV viral load; CD4 count | Every 3–6 months per standard HIV treatment monitoring guidelines |
Frequently Asked Questions
Why does rifampin cause HIV treatment failure when taken with Biktarvy?
Rifampin is one of the most potent inducers of CYP3A4 and P-glycoprotein in clinical use. Both systems are central to bictegravir pharmacokinetics: CYP3A4 is the primary metabolic enzyme and P-gp is the intestinal efflux transporter. Combined induction reduces bictegravir plasma AUC by approximately 75%, dropping concentrations below the protein-adjusted IC90 needed for full integrase inhibition. HIV replication resumes under partial INSTI pressure — the precise pharmacodynamic condition that selects for integrase resistance mutations at N155H and Q148K/R/H, which can confer cross-resistance across the entire INSTI class.
Why is dofetilide absolutely contraindicated with Biktarvy rather than managed with dose reduction?
Dofetilide is eliminated almost entirely by active renal secretion via MATE1 and MATE2-K transporters — the same renal efflux transporters that emtricitabine and bictegravir both inhibit. The resulting increase in dofetilide plasma concentrations extends its QT-prolonging effect; at elevated concentrations this produces excessive QT interval prolongation that precipitates torsades de pointes. Because dofetilide has an extremely narrow therapeutic index, there is no established dose adjustment that renders co-administration safe.
Which laboratory tests are indicated when Biktarvy is combined with metformin?
The primary investigation is renal function: eGFR and serum creatinine should be established at baseline and reassessed periodically. Biktarvy’s inhibition of OCT2 and MATE1 transporters raises metformin AUC by approximately 39% — a modest increase that is generally not clinically significant with normal renal function, though metformin accumulation is more likely in patients with compromised renal elimination, warranting closer monitoring. Serum lactate should be obtained urgently if the patient presents with unexplained fatigue, nausea, vomiting, abdominal pain, dyspnea, or cold extremities.
How does subtherapeutic bictegravir exposure lead to integrase resistance mutations?
Bictegravir requires sustained concentrations above the protein-adjusted IC90 to maintain full occupancy of the HIV integrase active site. When CYP3A4-inducing drug interactions reduce bictegravir below this threshold, integrase is only partially inhibited and HIV replication continues. Variants with substitutions reducing bictegravir binding affinity — at N155, Q148, and E92 — are selectively enriched under drug pressure. The Q148K/R/H pathway is of particular concern because it produces broad cross-resistance to dolutegravir and raltegravir.
Which statin is the preferred choice for a patient on Biktarvy?
Biktarvy contains no pharmacokinetic booster, so it does not carry the statin dose caps that apply to ritonavir- or cobicistat-boosted regimens, and its prescribing information documents no clinically significant statin interaction. Pravastatin and pitavastatin have the lowest interaction burden across HIV therapy and are reasonable first choices; atorvastatin and rosuvastatin can be used at standard doses with routine muscle-symptom awareness; and simvastatin and lovastatin are generally avoided in patients on antiretroviral therapy as a class-level precaution. Statin choice should follow standard lipid guidelines and each statin’s own label.
Can Biktarvy be continued during tuberculosis treatment?
Not with standard rifamycin-based TB therapy. Rifampin is absolutely contraindicated with Biktarvy due to a 75% reduction in bictegravir AUC sufficient to cause HIV treatment failure and resistance development. Rifabutin is not recommended either (38% AUC reduction). Current DHHS and WHO guidelines recommend a planned switch to a dolutegravir-based antiretroviral regimen before beginning rifamycin treatment.
Which antacids reduce Biktarvy absorption the most, and how should the doses be separated?
Aluminum/magnesium-containing antacids cause the largest reduction — bictegravir AUC falls by approximately 79% when the two are taken together on an empty stomach. The interaction is not symmetric in time: taking Biktarvy 2 hours before the antacid limits the reduction to roughly 13%, but taking Biktarvy 2 hours after the antacid still reduces AUC by about 52%. Biktarvy should therefore be taken at least 2 hours before, or at least 6 hours after, an aluminum- or magnesium-containing antacid.
Can you take calcium or iron supplements with Biktarvy?
Yes, when taken with food. Calcium and iron chelate bictegravir mainly on an empty stomach — taken simultaneously while fasting, calcium carbonate lowers bictegravir AUC by about 33% and ferrous fumarate (iron) by about 63%. Taking the supplement together with a meal neutralizes this effect, so calcium- or iron-containing products can be taken at the same time as Biktarvy with food, or otherwise separated by at least 2 hours. This differs from aluminum/magnesium antacids, which require strict timing separation regardless of food.
This article was reviewed by Dr. Ranjit Mohan, MBBS, MD, and written by Ray Ashton in accordance with SunnyPharma’s Editorial Policy. Content is reviewed for clinical accuracy, updated when guidelines change, and written to inform — not replace — the advice of a qualified healthcare provider.
References
- Gilead Sciences. Biktarvy US Prescribing Information. 2025.
- DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. clinicalinfo.hiv.gov
- University of Liverpool HIV Drug Interaction Database. Accessed July 2026.
- Arora P, et al. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug–drug interaction study. Antimicrob Agents Chemother. 2025.
- Cattaneo D, et al. Lack of clinically relevant interactions between bictegravir and metformin. J Antimicrob Chemother. 2021;76(7):1945.
- World Health Organization. Guidelines for Treatment of Drug-Susceptible Tuberculosis. 2022. who.int